Published in Curr Mol Med on January 01, 2012
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res (2014) 2.18
Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2013) 1.52
Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. J Control Release (2013) 1.46
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget (2014) 1.28
Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell (2014) 1.10
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer (2014) 0.96
Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis. Mol Cancer (2013) 0.96
SLUG: Critical regulator of epithelial cell identity in breast development and cancer. Cell Adh Migr (2014) 0.94
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One (2013) 0.94
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med (2013) 0.92
Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer. Am J Cancer Res (2013) 0.90
NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Cancer Res (2014) 0.90
A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients. PLoS One (2013) 0.86
Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS One (2015) 0.86
The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders. OMICS (2015) 0.86
Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun (2016) 0.85
An in vitro-in vivo model of epithelial mesenchymal transition in triple negative breast cancer. Drug Discov Today Dis Mech (2012) 0.83
Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis. ACS Nano (2015) 0.81
On-command drug release from nanochains inhibits growth of breast tumors. Pharm Res (2013) 0.79
Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis. J Pharm Sci (2015) 0.79
Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health (2012) 0.77
Mammary Development and Breast Cancer: A Wnt Perspective. Cancers (Basel) (2016) 0.77
The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis. Oncogene (2015) 0.77
Factors Associated with (18)F-Fluorodeoxyglucose Uptake in T1 and T2 Invasive Ductal Carcinoma of the Breast. Nucl Med Mol Imaging (2016) 0.75
Targeting the sumoylation pathway in cancer stem cells. Mol Cell Oncol (2014) 0.75
A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv (2017) 0.75
An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer. Mol Oncol (2015) 0.75
Difference in therapeutic response between basal and nonbasal triple-negative breast cancers. Oncologist (2013) 0.75
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. Anticancer Drugs (2015) 0.75
p16 expression correlates with basal-like triple-negative breast carcinoma. Ecancermedicalscience (2013) 0.75
The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. Contemp Oncol (Pozn) (2016) 0.75
Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. Oncotarget (2016) 0.75
Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. BMC Med Genomics (2017) 0.75
Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers: initial evidence of an oncogenic role for CHD7. Mol Oncol (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol (2006) 6.07
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 4.94
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Triple-negative breast cancer: therapeutic options. Lancet Oncol (2007) 4.80
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer (2007) 4.74
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem (2000) 4.49
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 4.38
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol (2005) 4.31
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat (2007) 3.83
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 3.59
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
How basal are triple-negative breast cancers? Int J Cancer (2008) 3.18
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res (2007) 3.01
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol (2006) 2.92
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Integrated profiling of basal and luminal breast cancers. Cancer Res (2007) 2.86
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics (2006) 2.86
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol (2008) 2.85
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res (2001) 2.76
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res (2003) 2.51
The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst (2004) 2.49
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res (2005) 2.43
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res (2006) 2.34
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res (2005) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1. Nature (1983) 4.44
New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol (1984) 3.43
ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol (2000) 2.90
BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene (1991) 2.89
Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia (2009) 2.77
Histoprognostic grade in BRCA1-associated breast cancer. Lancet (1995) 2.47
Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol (1998) 2.40
WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene (2001) 2.32
Characterization of the HST-related FGF.6 gene, a new member of the fibroblast growth factor gene family. Oncogene (1989) 2.20
Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet (2000) 2.15
Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer (1995) 2.05
Characterization of an activated human ros gene. Mol Cell Biol (1986) 1.97
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet (1999) 1.96
Mesenteric panniculitis: review of the leterature and presentation of cases. Surgery (1977) 1.83
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia (2013) 1.65
Collective nomenclature for LAP proteins. Nat Cell Biol (2000) 1.64
Ancient large-scale genome duplications: phylogenetic and linkage analyses shed light on chordate genome evolution. Mol Biol Evol (1998) 1.57
Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol (1997) 1.51
Detailed map of a region commonly amplified at 11q13-->q14 in human breast carcinoma. Cytogenet Cell Genet (1997) 1.48
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia (2009) 1.45
Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene (1991) 1.44
Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene (2008) 1.44
Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo. Development (1993) 1.41
Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Hum Mol Genet (1999) 1.39
Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res (1998) 1.39
Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene (1999) 1.39
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 1.38
Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease. J Pathol (1996) 1.38
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood (1992) 1.37
Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol (2004) 1.33
Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res (1997) 1.33
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 1.32
The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene (1993) 1.32
Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood (1997) 1.30
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer (2000) 1.30
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res (2000) 1.29
Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer (1994) 1.27
Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia (2008) 1.27
Submicrometer intracellular chemical optical fiber sensors. Science (1992) 1.26
Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene (2006) 1.23
Murine FGF-12 and FGF-13: expression in embryonic nervous system, connective tissue and heart. Mech Dev (1997) 1.22
The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood (1999) 1.21
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res (1996) 1.21
Structure and expression of human fibroblast growth factor-10. J Biol Chem (1997) 1.20
FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood (2000) 1.20
Influence of mood on health-relevant cognitions. J Pers Soc Psychol (1989) 1.19
Extracorporeal pumpless interventional lung assist in clinical practice: determinants of efficacy. Eur Respir J (2008) 1.17
Localization of the mcf.2 transforming sequence to the X chromosome. EMBO J (1987) 1.16
Fibroblast growth factor gene expression in AIDS-Kaposi's sarcoma detected by in situ hybridization. Am J Pathol (1991) 1.16
The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins. J Biol Chem (2001) 1.16
FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia (1998) 1.15
Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene (2006) 1.15
Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J (1992) 1.14
Homeobox gene clusters and the human paralogy map. FEBS Lett (2001) 1.13
Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas. Oncogene (1989) 1.12
Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer (2009) 1.12
Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer (1994) 1.11
Myelodysplastic syndromes: lost between two states? Leukemia (2010) 1.11
Evidence for a third breast-cancer susceptibility gene. Lancet (1994) 1.09
Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene. Genomics (1992) 1.08
Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene (1995) 1.08
Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene (2006) 1.08
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
HLA cosmid clones show complete, widely spaced human class I genes with occasional clusters. Gene (1982) 1.07
Corneal endothelial permeability after anterior chamber silicone oil. Ophthalmology (1990) 1.05
The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell Growth Differ (1994) 1.05
Chromosomal localization of the hst oncogene and its co-amplification with the int.2 oncogene in a human melanoma. Oncogene (1988) 1.04
Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol (1996) 1.04
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene (2007) 1.04
Relation between bicarbonate concentration and rate of canine pancreatic secretion. Am J Physiol (1965) 1.03
Expression of human class I histocompatibility antigens at the surface of DNA-transformed mouse L cells. Immunogenetics (1982) 1.03
NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia (2007) 1.03
Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog (1993) 1.03
let-756, a C. elegans fgf essential for worm development. Oncogene (1999) 1.02
MetaHox gene clusters. J Exp Zool (2000) 1.01
Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer (1995) 1.01
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J (2011) 1.01
Patterns of loss of heterozygosity at loci from chromosome arm 13q suggests a possible involvement of BRCA2 in sporadic breast tumors. Genes Chromosomes Cancer (1995) 1.01
Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia (2008) 1.01
Structure and developmental expression of mouse Garp, a gene encoding a new leucine-rich repeat-containing protein. Int J Dev Biol (1996) 1.01
DNA amplification at 11q13 in human cancer: from complexity to perplexity. Mutat Res (1992) 1.00
The family of Caenorhabditis elegans tyrosine kinase receptors: similarities and differences with mammalian receptors. Genome Res (1999) 1.00
Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J Biol Chem (1999) 1.00
Mutations and deletions of ARID1A in breast tumors. Oncogene (2012) 1.00
[Aggregation and separability of the shikimate pathway enzymes in yeasts]. Z Allg Mikrobiol (1981) 0.99
Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene (1993) 0.99
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer (2007) 0.98
[Pumpless extracorporeal lung assist using arterio-venous shunt in severe ARDS. Experience with 30 cases]. Anaesthesist (2004) 0.98
Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene (2011) 0.98